A neutralizing RNA aptamer against EGFR causes selective apoptotic cell death

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Nucleic acid aptamers offer high-affinity, specific targeting of disease-associated proteins.
• Epidermal growth factor receptor (EGFR) is a key target in various cancers, but current inhibitors face toxicity and resistance issues.
• Novel EGFR-targeting agents with improved specificity and reduced toxicity are needed.

Purpose of the Study:

• To generate and characterize a nuclease-resistant RNA aptamer targeting EGFR.
• To evaluate the efficacy of the aptamer in inhibiting EGFR-expressing cancer cells and tumors.
• To assess the potential of the aptamer as an alternative or adjunct cancer therapy.

Main Methods:

• Cell-SELEX (Systematic Evolution of Ligands by EXponential enrichment) was used to generate the RNA aptamer.
• Binding affinity to EGFR was determined (10 nM).
• In vitro and in vivo studies assessed aptamer's effect on cancer cell signaling, apoptosis, and tumor growth in a non-small-cell lung cancer (NSCLC) xenograft model.

Main Results:

• A specific, nuclease-resistant RNA aptamer targeting EGFR was successfully generated.
• The aptamer inhibited EGFR-mediated signaling pathways, induced selective cancer cell death, and apoptosis in drug-resistant cells.
• The aptamer demonstrated efficacy in reducing tumor growth in vivo and synergistic effects when combined with cetuximab.

Conclusions:

• The developed RNA aptamer is a potent EGFR inhibitor with high specificity and low toxicity.
• This aptamer represents a promising therapeutic candidate for EGFR-driven cancers, including those resistant to current treatments.
• Combined aptamer and cetuximab therapy shows enhanced efficacy, suggesting a potential for combination strategies.